No Data
shenzhen prince new materials (002735) 2024 third quarter report review: non-recurring net income attributable to mother increased by 22.92% year-on-year, the construction of the private placement project is expected to break through the production capaci
Event: The company released its third quarter report. In the first three quarters of 2024, the company achieved revenue of 1.312 billion yuan, up 9.42% year-on-year, and achieved a net income attributable to the parent company of 0.013 billion yuan, down 25.84% year-on-year; achieving non-recurring net income
Prince New Materials: Report for the third quarter of 2024
Shenzhen Prince New Materials (002735.SZ): The net income for the first three quarters was 12.883 million yuan, a year-on-year decrease of 25.84%.
On October 25, Gelunhui announced shenzhen prince new materials (002735.SZ) third-quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 1.312 billion yuan, a year-on-year increase of 9.42%; net income attributable to shareholders of the listed company was 12.883 million yuan, a year-on-year decrease of 25.84%; net income after deducting non-recurring gains and losses was 15.0484 million yuan, a year-on-year increase of 22.92%; and the basic earnings per share were 0.03 yuan/share.
Shenzhen Prince New Materials (002735.SZ) released its performance for the first three quarters, with a net income of 12.883 million yuan, a year-on-year decrease of 25.84%.
Shenzhen Prince New Materials (002735.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
Express News | shenzhen prince new materials: intends to acquire 15% equity of Dongguan Qunzan
It is expected that relevant national authorities will establish a low-altitude economic regulatory bureau.
①The establishment decision has been approved, and the new bureau is currently in preparation; ② The low-altitude economy set up a dedicated bureau, which can better coordinate resources at all levels to promote industrial development.
No Data
No Data